Effect of a soluble prebiotic fiber, NUTRIOSE, on the absorption of ginsenoside Rd in rats orally administered ginseng

Kyung-Ah Kim$^1,\dagger$, Hye Hyun Yoo$^2,\ddagger$, Wan Gu$^1$, Dae-Hyung Yu$^1$, Ming Ji Jin$^2$, Hae-Lim Choi$^3$, Kathy Yuan$^4$, Laetitia Guerin-Deremaux$^5$, Dong-Hyun Kim$^1,\star$

$^1$Department of Pharmacy, College of Pharmacy, Kyung Hee University, Dongdaemun-gu, Seoul, Korea
$^2$Department of Pharmacy, College of Pharmacy, Hanyang University, Ansan, Gyeonggi-do, Korea
$^3$Roquette Korea Ltd, Teheran-ro, Gangnam-gu, Seoul, Korea
$^4$Roquette Management (Shanghai) Co., Ltd, K. Wah Centre, Shanghai, China
$^5$Biology and Nutrition department, Roquette Frères, Rue de la Haute Loge, Lestrem, France

1. Introduction

Orally administered herbal medicines and functional foods inevitably come in contact with intestinal microbiota [1,2]. The intestinal microbiota are influenced by endogenous and exogenous factors, such as diet, drugs, stress, etc, and they metabolize endogenous compounds secreted into the gastrointestinal tract and orally administered exogenous xenobiotics, such as constituents of herbal medicines and functional foods [3–5]. Thus, intestinal microbiota transform constituents of herbal medicines and functional foods to bioactive compounds prior to absorption [2,6,7].

Ginseng (the root of Panax ginseng Meyer, Araliaceae) is frequently used as a herbal medicine and functional food, and ginsenosides, the major constituents, exhibit a spectrum of biological effects, including anti-inflammatory and antitumor activity [2,8,9]. Ginsenosides need to be metabolically activated by human intestinal microbes to express their biological effects [10,11].

---

* Corresponding author. Department of Life and Nanopharmaceutical Sciences and Department of Pharmaceutical Science, College of Pharmacy, Kyung Hee University, 1, Hoegi, Dongdaemun-ku, Seoul 130-701, Korea.
$\dagger$ E-mail address: dhhkim@khu.ac.kr (D.-H. Kim).
$\ddagger$ These authors contributed equally.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

1226-8453/$e$ see front matter Copyright © 2014, The Korean Society of Ginseng, Published by Elsevier. All rights reserved.

http://dx.doi.org/10.1016/j.jgr.2014.03.003
Ginsenosides, Rg1, Rb1, Rb2, and Rg3 are metabolized primarily to ginsenoside Rd by human intestinal microbiota (Fig. 1) [6,7,12]. Ginsenoside Rd exhibits potent anti-inflammatory, anti-obesity, and anti-ischemic effects [13–15], and it is further metabolized to ginsenoside F2 and compound K, which also possess pharmacological activity. Intestinal microbes, therefore, play an important role in the observed pharmacological effects of ginseng. Furthermore, the gastrointestinal absorption of ginseng constituents and metabolites in humans and animals is influenced by regulators of intestinal microbiota such as diet and drugs. Therefore, the effect of diet and subsequent alterations in intestinal bacterial metabolic activities on the pharmacokinetic behaviors of ginsenosides needs to be studied in detail.

NUTRIOSE, used as a food ingredient, is a soluble prebiotic fiber derived from wheat and corn. NUTRIOSE administered orally to healthy men is partially digested (up to 15%) in the small intestine and progressively fermented (up to 75%) in the colon [16]. NUTRIOSE also increased colony counts of intestinal Lactobacillus spp. [16–18]. In human individuals given short- and long-term NUTRIOSE supplemnations, fecal α/β-glucosidase activities were significantly increased and symptoms of intestinal bowel disease were improved through a protective immune effect.

In the present study, we studied the pharmacokinetics of ginsenoside Rd after oral administration of ginsenoside Rb1 or ginseng extract with or without NUTRIOSE pretreatment in rats, to understand the effect of diet on the relationship between intestinal bacterial metabolic conversion of ginsenosides to ginsenoside Rd and the absorption of ginsenoside Rd into the blood.

2. Materials and methods

2.1. Materials

Ginseng extract was prepared according to the method described by Bae et al [12]. Briefly, the dried root of Panax ginseng Meyer (1 kg) produced at Kumsan (Chungnam, Korea) was extracted with 70% ethanol twice, concentrated, and freeze-dried (yield, 18%). The extracted powder contained 8.9% ginsenoside Rb1 and 1.4% ginsenoside Rd. The ethanol extract was suspended in water and successively extracted with hexane and butanol. The butanol fraction was separated by silica gel column chromatography to yield ginsenosides Rb1 (purity > 94%, 8 mg) and Rd (purity > 92%, 52 mg).

NUTRIOSE, a mixture of glucose polymers with a fairly narrow molecular weight range (number-average molecular weight, 200–4000 Da; weight-average molecular weight, 4000–6000; degree of polymerization, 12–25), was kindly donated from Roquette (Les-trem, France).

2.2. Assay of fecal metabolism of ginsenoside Rb1 to ginsenoside Rd

Rat fecal specimens (n = 5, approximately 0.2 g) were collected in plastic cups and suspended in 1.8 mL cold saline [19]. The fecal bacterial suspension was centrifuged at 500 × g for 5 min, and the resultant supernatant was sonicated and centrifuged at 10,000 × g for 30 min. The resultant supernatant was used as a crude enzyme solution.

To investigate the effect of diet on the metabolic activation of ginsenoside Rb1 to ginsenoside Rd by intestinal microbiota cultured in Gifu anaerobic broth (GAM broth), the fresh stool specimen was suspended in GAM broth and centrifuged at 500 × g. The resultant supernatant was inoculated in dextrose (1%) or NUTRIOSE (1%) containing GAM broth (glucose-free broth) and cultured for 24 h. The cultured media was collected by centrifigation (10,000 × g, 20 min). The precipitate was used as the crude enzyme for assaying the metabolism of ginsenoside Rb1 to Rd. The generated Rd was assayed by high performance liquid chromatography (HPLC).

For assaying the contribution of fecal activity in the metabolism of ginsenoside Rb1 to ginsenoside Rd, a reaction mixture (2 mL) containing 0.2 mL of the fecal culture prepared from freshly collected rat feces (n = 5) and 0.2 mL of 0.1mM ginsenoside Rb1 was incubated at 37°C for 1 h, which was followed by the addition of 2 mL of MeOH to stop the reaction. The reaction mixture was centrifuged at 3000 × g for 10 min, and the levels of ginsenoside Rb1 and its metabolite ginsenoside Rd in the resultant supernatant were analyzed by HPLC. The HPLC system was as follows: a Hewlett Packard series 1050 module, a UV detector (Ramsey, MN, USA) set at 203 nm, a Hypersil ODS column (4.6 × 150 mm i.d., 5.0 µm; Agilent, Santa Clara, CA, USA), linear-gradient mixture of 30% water and 70% acetonitrile for 15 min as elution solvent, flow rate of 1.0 mL/min, and injection volume of 20 µL.

2.3. Animals

Male Sprague–Dawley rats (210–240 g) were supplied by the Orient Experimental Animal Breeding Center (Gyunggi-do, Korea). All animals were housed in wire cages (2 rats per cage) kept at a temperature of 20–22°C and 50 ± 10% humidity, fed standard laboratory chow (Samyang Co., Seoul, Korea), and allowed water ad libitum. All experiments were performed in accordance with the National Institutes of Health and Kyung Hee University Guides for Experimental Animal Care.
Laboratory Animals Care and Use and approved by the Committee for the Care and Use of Laboratory Animals in the College of Pharmacy, Kyung Hee University (KHP-2012-04-06-R1).

2.4. Pharmacokinetic study

Each rat was orally fed ginsenoside Rb1, ginseng extract, or vehicle 2 h after the last dose of a 2-wk administration of a NUTRIOSE-containing control diet. Blood was collected (0.2 mL) from the tail vein at 0 h, 1 h, 2 h, 4 h, 8 h, 12 h, 16 h, 20 h, and 24 h after ginseng extract administration.

The rats were divided into 2 groups [either treated with vehicle alone (normal control, n = 5) or test agent (200 mg/kg ginsenoside Rb1, n = 5)] in a preliminary study and the remaining animals were later divided into seven groups as follows for a subsequent study: Group 1, NOR, group fed a control diet, n = 5; Group 2, N-NOR, group fed NUTRIOSE (control diet + NUTRIOSE 10%, n = 5); Group 3, G0.2, group treated with ginseng extract (200 mg/kg) after feeding a control diet, n = 5; Group 4, G2, group treated with ginseng extract (200 mg/kg) after feeding a control diet, n = 5; Group 5, N2.5-G2, group treated with ginseng extract (200 mg/kg) after feeding a control diet, n = 5; Group 6, N5-G2, group treated with ginseng extract (200 mg/kg) after feeding NUTRIOSE (control diet + NUTRIOSE 2.5%, n = 5); Group 7, N10-G2, group treated with ginseng extract (200 mg/kg) after feeding NUTRIOSE (control diet + NUTRIOSE 5%, n = 5); and Group 8, N2.5-G2, group treated with ginseng extract (200 mg/kg) after feeding NUTRIOSE (control diet + NUTRIOSE 10%, n = 5) in a second substudy. The control diet or NUTRIOSE-containing control diet was administered for 2 wk prior to starting treatment with the ginseng extract.

2.5. Sample preparation and calibration curves

Blood samples were centrifuged for 10 min at 4,000 × g to separate the plasma. The plasma samples (20 μL) were deproteinated with the same volume of acetonitrile for ginsenoside Rd detection. The supernatants were evaporated to dryness under a gentle N2 stream at 50°C. The residue was reconstituted with 50 μL of 50% methanol. A 2-μL aliquot was injected into the liquid chromatography tandem mass spectroscopy (LC–MS/MS) system. Calibration standards were prepared by spiking 10 μL of working solutions into 90 μL of rat blank plasma over a concentration range of 5–1,000 ng/mL. The calibration curves were generated by plotting the peak area ratios of the analytes to the internal standard vs. the concentrations of analytes, by least-square linear regression. Each standard was prepared in triplicate. The correlation coefficients of the calibration curves were greater than 0.99. The calibration curve equation for ginsenoside Rd was $y = 9.94 \times 10^{-6}x + 3.8 \times 10^{-5}$.

2.6. HPLC-MS/MS instrumentation

For the analysis of ginsenoside Rd, HPLC-MS/MS analyses were performed on Agilent Technologies 1260 Infinity HPLC-6460 Triple Quad Mass Spectrometer (Palo Alto, CA, USA). Chromatographic separation of the sample was performed on a Hypersil BDS C18 column (50 mm × 2.1 mm internal diameter, 5 μL; Thermo Scientific, Waltham, MA, USA). For elution, a linear gradient was applied: CH3CN–H2O (40:60, v/v) to CH3CN–H2O (95:5, v/v) for 10 min. The flow rate was 0.3 mL/min. Mass spectra were acquired in a positive mode using nitrogen gas at a temperature of 300°C, flow rate of 10 L/min, nebulizer pressure of 20 psi, quadrupole temperature of 30°C, and capillary voltage of 4000 V. The precursor–product ion pairs monitored were 969→789 for ginsenoside Rd and 409→238 for the internal standard (amlodipine).

2.7. Pharmacokinetic analysis

The maximum plasma concentration (Cmax) and time to reach maximum drug concentration (Tmax) for ginsenoside Rd were estimated directly from the plasma concentration–time profiles. Area under the plasma drug concentration–time curve (AUC) was calculated by using the log-linear trapezoidal rule for the total period and extrapolated to infinity.

Table 1

| Group | Tmax (h) | Cmax (ng/mL) | AUC (ng·h/mL) |
|-------|---------|--------------|---------------|
| Rb0.2 | 10.6 ± 2.3 | 72.4 ± 31.6 | 683.9 ± 285.3 |
| G0.2  | 9.6 ± 5.3  | 690.4 ± 473.0 | 897.4 ± 379.9 |
| G2    | 11.2 ± 5.2  | 906.5 ± 330.2 | 11377.3 ± 4470.2 |
| N2.5-G2 | 8.4 ± 5.0  | 982.2 ± 455.9 | 12882.3 ± 8086.5 |
| N5-G2  | 6.0 ± 4.0  | 1079.5 ± 422.1 | 12281.0 ± 7062.0 |
| N10-G2 | 8.0 ± 4.0  | 1220.3 ± 796.5 | 15213.3 ± 6086.7 |

Group labels are as mentioned in Figs. 4 and 5. AUC, area under the blood concentration curve; Cmax, maximum plasma concentration; Tmax, maximum drug concentration time.
3. Results

3.1. Fecal metabolic activities of rats for ginsenoside Rb1 in vitro

To confirm the ability of intestinal microflora to metabolize ginsenosides to ginsenoside Rd, we measured ginsenoside Rd levels after exposure of rat feces to ginsenoside Rb1 (Fig. 2). The activity of feces in metabolizing ginsenoside Rb1 to ginsenoside Rd ranged from 927 nmol/h/g to 970 nmol/h/g, and the mean activity was 955 nmol/h/g.

3.2. Pharmacokinetic study of ginsenoside Rd in rats orally treated with ginsenoside Rb1 or ginseng extract

To investigate whether the metabolite ginsenoside Rd is absorbed into the blood in rats orally administered with ginsenoside Rb1, we orally administered ginsenoside Rb1 (200 mg/kg) or ginseng extract (200 mg/kg or 2,000 mg/kg) to rats and then periodically measured the plasma concentration of ginsenoside Rd, which is a ginsenoside Rb1 metabolite (Fig. 3). When the rats were administered with ginsenoside Rb1 (200 mg/kg), the Tmax of ginsenoside Rd was 10.6 ± 2.3 h and the Cmax and AUC of ginsenoside Rd were 72.4 ± 31.6 ng/mL and 663.9 ± 285.3 ng h/mL, respectively (Table 1).

When ginseng extract was administered at 200 mg/kg or 2,000 mg/kg, the Cmax and AUC of ginsenoside Rd were found to be 690.4 ± 473.0 ng/mL and 8974.2 ± 379.9 ng h/mL, respectively, in rats treated with 200 mg/kg ginseng extract and, 906.5 ± 330.2 ng/mL and 11377.3 ± 4470.2 ng h/mL, respectively, in rats treated with 2,000 mg/kg ginseng extract, respectively (Fig. 4, Table 1). However, the differences in Cmax and AUC of ginsenoside Rd between rats treated with 200 mg/kg and 2,000 mg/kg ginseng extract were not significant.

3.3. Effect of NUTRIOSE on the pharmacokinetic parameters of ginsenoside Rd in rats orally treated with ginseng extract

To understand the effect of diet on the absorption of the metabolite ginsenoside Rd into the blood, we measured the plasma concentration of ginsenoside Rd in ginseng extract-treated rats fed with or without pretreatment with NUTRIOSE for 2 wk. We detected ginsenoside Rd when ginseng extract was orally administered in rats both with and without NUTRIOSE pretreatment (Fig. 5). We could detect ginsenoside Rd at 2 h after administration of ginseng extract in rats not fed NUTRIOSE. We also found that NUTRIOSE increased the blood concentration of ginsenoside Rd as compared with that in the normal control group by up to 30%, although the difference between groups was not statistically significant due to large individual variations (Table 1).

3.4. Effect of NUTRIOSE on the metabolic conversion of ginsenoside Rb1 to ginsenoside Rd by rat fecal microbiota cultured in GAM

To further investigate whether NUTRIOSE could induce rat fecal metabolic activity in the conversion of ginsenoside Rb1 to ginsenoside Rd, we cultured fecal microbiota of rats in GAM broth with or without NUTRIOSE for 24 h and measured the ginsenoside Rd-
forming activity (Fig. 6). The cultured fecal microbiota of rats potently hydrolyzed ginsenoside Rb1 to ginsenoside Rd when NUTRIOSE was added. When rat fecal microbiota was cultured in 1% NUTRIOSE-containing GAM broth, the metabolism of ginsenoside Rb1 to ginsenoside Rd was induced 3.4 fold (3.4 ± 1.8, p = 0.04) compared with microbiota cultured in dextrose-containing GAM broth.

4. Discussion

Ginseng contains many hydrophilic ginsenosides, which are metabolized to hydrophobic bioactive compounds before absorption into the blood [2]. For example, ginsenosides Ra1, Ra, Rb1, Rb2, Rc, and Rd are metabolized to compound K via ginsenoside Rd by intestinal microbiota of humans and rats. Therefore, to understand the complete spectrum of the pharmacological activities of ginseng, it is important to first understand the metabolism of ginsenosides and study the absorption pattern of the metabolites into systemic circulation. In the present study, we measured ginsenoside Rd, a metabolite of ginsenoside Rb1, in rats orally treated with ginsenoside Rb1. We could also detect the important metabolite ginsenoside Rd after exposure of ginsenoside Rb1 to intestinal microbiota. This metabolite was also detected in rats orally treated with ginseng extract. In previous clinical studies, ginsenoside Rd was detected when G115, a ginseng saponin fraction, was administered orally [20]. We detected ginsenoside Rd 8 h after administration of 10% NUTRIOSE in the diet caused AUC and Cmax of ginsenoside Rd to increase 1.34-fold. Furthermore, Tmax was shorter in NUTRIOSE-fed rats than in normal diet-treated ones.

In conclusion, the absorption of bioactive metabolite ginsenoside Rd in rats orally administered with ginsenoside Rb1 or ginseng extract was dependent on the metabolic activity of gastrointestinal microflora. Furthermore, oral administration of a prebiotic NUTRIOSE can stimulate the intestinal bacterial metabolic conversion of ginsenoside Rb1 to ginsenoside Rd to improve the absorption of ginsenoside Rd.

Conflicts of interest

All authors declare no conflicts of interest.

References

[1] Crow JM. Microbiome: that healthy gut feeling. Nature 2011;480:588–9.
[2] Kim DH. Chemical diversity of Panax ginseng, Panax quinquefolium, and Panax notoginseng. J Ginseng Res 2012;36:1–15.
[3] Scheline RR. Metabolism of foreign compounds by gastrointestinal microorganisms. Pharmacol Rev 1973;25:451–523.
[4] Mikov M. The metabolism of drugs by the gut flora. Eur J Drug Metab Pharmacokinet 1994;19:201–7.
[5] Sousa T, Paterson R, Moore V, Carlsson A, Abrahamsson B, Basit AW. The gastrointestinal microbiota as a site for the biotransformation of drugs. Int J Pharm 2008;363:1–25.
[6] Akao T, Kanaoka M, Kobashi K. Appearance of compound K, a major metabolite of ginsenoside Rb1 by intestinal bacteria, in rat plasma after oral administration—measurement of compound K by enzyme immunoassay. Biol Pharm Bull 1998;21:245–9.
[7] Akao T, Kida H, Kanaoka M, Hattori M, Kobashi K. Intestinal bacterial hydrolysis is required for the appearance of compound K in rat plasma after oral administration of ginsenoside Rb1 from Panax ginseng. J Pharm Pharmacol 1998;50:1155–60.
[8] Juh ET, Lee IA, Jung IH, Kim DH. Ginsenoside Rb1 and its metabolite compound K inhibit IRAK-1 activation—the key step of inflammation. Biochem Pharmacol 2011;82:278–86.
[9] Choo MK, Sakurai H, Kim DH, Saiki J. A ginseng saponin metabolite suppresses tumor necrosis factor-alpha-promoted metastasis by suppressing nuclear factor-kappaB signaling in murine colon cancer cells. Oncol Rep 2008;19:595–600.
[10] Wakabayashi C, Murakami K, Hasegawa H, Murata J, Saiki L. An intestinal bacterial metabolite of ginseng protopanaxadisol saponins has the ability to induce apoptosis in tumor cells. Biochem Biophys Res Commun 1998;246:225–30.
[11] Shin YW, Kim DH. Antiproliferative effect of ginsenoside Rb1 and compound K in scratching behavior mouse models. J Pharmaco Sci 2005;95:83–8.
[12] Bae EA, Park SY, Kim DH. Constitutive beta-glucosidases hydrolyzing ginsenoside Rb1 and Rb2 from human intestinal bacteria. Biol Pharm Bull 2000;23:1451–5.
[13] Wang L, Zhang Y, Wang Z, Li S, Geng W, Li J, Cheng J, Wu Y. Inhibitory effect of ginsenoside-Rd on carrageenan-induced inflammation in rats. Can J Physiol Pharmacol 2012;90:299–306.
[14] Liu X, Wang L, Wen A, Yang J, Yan Y, Song Y, Liu X, Ren H, Wu Y, Li Z, et al. Ginsenoside-Rd improves outcome of acute ischaemic stroke—a randomized, double-blind, placebo-controlled, multicenter trial. Eur J Neurosci 2012;19:155–63.
[15] Yang XL, Guo TK, Wang YH, Huang YH, Liu X, Wang XX, Li W, Zhao X, Wang LP, Yan S, et al. Ginsenoside Rd attenuates the inflammatory response via modulating p38 and JNK signaling pathways in rats with TNBS-induced relapsing colitis. Int Immunopharmacol 2012;12:408–14.
[16] van den Heuvel EC, Wils D, Pasman WJ, Saniez MH, Kardinaal AF. Dietary supplementation of different doses of NUTRIOSE FB, a fermentable dextrin, alters the activity of faecal enzymes in healthy men. Eur J Nutr 2005;44:445–51.
[17] Lefranc-Millot C. NUTRIOSE 06: a useful soluble dietary fibre for added nutritional value. Nutrition Bulletin 2008;33:234–9.
[18] Lefranc-Millot C, Guérin-Deremaux I, Wils D, Neut C, Miller LE, Saniez-Degrave MH. Impact of a resistant dextrin on intestinal ecology: how altering the digestive ecosystem with NUTRIOSE, a soluble fibre with prebiotic properties, may be beneficial for health. Int J Med Res 2012;40:211–24.
[19] Choi JR, Hong SW, Kim Y, Jang SE, Kim MJ, Han MJ, Kim DH. Metabolic activities of ginseng and its constituents, ginsenoside Rb1 and Rg1, by human intestinal microflora. J Ginseng Res 2011;35:301–7.
[20] Tawab MA, Bahar U, Karas M, Wurglics M, Schubert-Zsilavecz M. Degradation of ginsenosides in humans after oral administration. Drug Metab Dispos 2003;31:1065–71.